Abstract
Opicapone is an oral, once-daily, selective catechol-O-methyltransferase (COMT) inhibitor, approved as an adjunctive treatment to levodopa/carbidopa (LD/CD) in patients with Parkinson’s disease (PD) experiencing “OFF” episodes. OPTI-ON (OPicapone Treatment Initiation OpeN-Label Study) was a “real-world” study of opicapone use in the US that evaluated the characteristics, treatment patterns, and safety/tolerability of patients initiating opicapone treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
